RESEARCH NOTE

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]

Albane Joly-Battaglini¹,², Clara Hammarström³, Branislava Stankovic¹,², Henrik Aamodt¹,²,⁴, Johan Stjärne⁵, Odd Terje Brustugun⁶, Åslaug Helland⁶,⁷, Inger Øynebråten¹,², Alexandre Corthay¹,²,⁸

¹Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway
²Centre for Immune Regulation, University of Oslo, Oslo, Norway
³Department of Pathology, Oslo University Hospital, Oslo, Norway
⁴Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway
⁵Betanien Hospital, Skien, Norway
⁶Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
⁷Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
⁸Department of Biosciences, University of Oslo, Oslo, Norway

Abstract
Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in which normal B cells have a pathogenic role, such as rheumatoid arthritis and multiple sclerosis. It is well-established that rituximab efficiently eliminates B cells in blood, lymph nodes, and spleen. In contrast, the effect of rituximab in non-lymphoid tissues remains poorly documented and is debated. Here, we report a rheumatoid arthritis patient who was treated with rituximab before receiving thoracic surgery for non-small cell lung cancer. Using flow cytometry and immunohistochemistry, we show that rituximab efficiently depleted CD20-positive B cells in a primary lung tumor, in lung-associated lymph nodes, and in normal lung tissue. We conclude that rituximab may be very efficient at depleting normal B cells in the lungs. This property of rituximab may potentially be exploited for the treatment of conditions in which pathogenic B cells reside in the lungs. On the other hand, the clearance of lung B cells may provide an explanation for the rare cases of severe non-infectious pulmonary toxicity of rituximab.

Keywords
rituximab, B cells, depletion, monoclonal antibody, lungs, tumor, lymph node, non-small cell lung cancer

Open Peer Review

Referee Status: ✔ ✔

Invited Referees
1
2

version 1
published
08 Jan 2016
report
report

1 Bertrand Huard, Joseph Fourier
University, France
2 Hilde Schjerven, University of California, San Francisco, USA
Etapong Fonabei Ayongaba, University of California, San Francisco, USA
University of Oslo, Norway

Discuss this article

Comments (2)
Corresponding author: Alexandre Corthay (alexandre.corthay@ibv.uio.no)

Competing interests: The authors declare that they have no competing interests.

How to cite this article: Joly-Battaglini A, Hammarström C, Stankovic B et al. Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved] F1000Research 2016, 5:38 (doi: 10.12688/f1000research.7599.1)

Copyright: © 2016 Joly-Battaglini A et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: This work was supported by grants from the Research Council of Norway, Norway Grants 2009-2014 under project contract NFI/R/2014/051 (to A. Corthay), and the Norwegian Cancer Society.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Introduction
Rituximab was the first monoclonal antibody to be approved for the treatment of cancer and it is estimated that >4 million people have been treated with rituximab worldwide. Rituximab is a depleting chimeric anti-CD20 monoclonal antibody routinely used for the treatment of B-cell lymphoma. The B cell-specific antigen CD20 is expressed on all normal B cells, except for early B cell precursors and antibody-secreting plasma cells, and by nearly all B-cell lymphomas. Since rituximab depletes both malignant and normal B cells, its use has been extended to non-cancerous conditions in which normal B cells are believed to play a central role in pathogenesis. Significant clinical benefits have been reported for the treatment of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, vasculitis, Sjögren’s syndrome, and scleroderma. The mechanism whereby rituximab depletes B cells is not fully understood but there is evidence for complement-dependent cell lysis and for antibody-dependent cellular cytotoxicity. It has been shown that rituximab efficiently eliminates normal and malignant B cells in blood and in lymphoid organs such as lymph nodes, spleen, and bone marrow. In contrast, the effect in non-lymphoid tissues remains poorly documented. Here, we report the effect of rituximab in the lungs of a patient who was treated with rituximab because of rheumatoid arthritis before receiving thoracic surgery for non-small cell lung cancer.

Methods

Ethics approval
The Regional Committee for Medical and Health Research Ethics (Oslo, Norway) has approved the study (permit number: REK S-05307). Written informed consent for publication of the clinical details was obtained from all patients included in the study.

Flow cytometry

Patient blood was sampled from a central venous catheter before the start of surgery and collected into ethylenediaminetetraacetic acid (EDTA)-containing tubes. Peripheral blood mononuclear cells (PBMCs) were isolated using a gradient (Lymphoprep, Axis-Shield, Oslo, Norway; cat. no. 1114544). Fresh biopsies from the tumor, a lung-associated lymph node, and normal lung tissue, were sampled under sterile conditions in the operating room, after the removal of the lung lobe by the surgeon. Samples were treated enzymatically with collagenase A, cat. no. 10103586001; DNase, cat. no. 11284932001) and incubated for 1 h on a magnet stirrer at 37°C. Single-cell suspension was obtained by squeezing the lung tissue through a 100 μm mesh and centrifuging at 300g for 7 min. Nonspecific binding was blocked by incubation with 12.5 μg/ml IgG purified from pooled mouse sera (Sigma-Aldrich, St. Louis, Missouri, USA; cat. no. I8765). Cells were stained in a 96-well plate for 20 min on ice with fluorochrome-labeled monoclonal antibodies diluted 1:10 in phosphate-buffered saline (Sigma-Aldrich, cat. no. D8537) supplemented with 10% foetal bovine serum (Sigma-Aldrich cat. no. F7524). The following monoclonal antibodies were used (all from BioLegend, San Diego, California, USA): anti-CD3 (clone UCHT1, cat. no. 300415); anti-CD4 (clone OKT4, cat. no. 317409); anti-CD8 (clone SK1, cat. no. 344713); anti-CD14 (clone HCD14, cat. no. 325617); anti-CD19 (clone HIB19, cat. no. 302227); anti-CD45 (clone HI30, cat. no. 304029); anti-HLA-DR (clone L243, cat. no. 307610). Stained cells were analyzed with a BD LSRFortessa Cell Analyzer instrument (BD Biosciences, Franklin Lakes, New Jersey, USA, model no. 647794E6) and FlowJo software version 10 (FlowJo, Ashland, Oregon, USA).

Tissue preparation and immunohistochemistry

For light microscopy, 4 μm thick sections from formalin-fixed paraffin-embedded tissue were automatically stained with hematoxylin and eosin in a Sakura Tissue-Tek Prisma instrument (Sakura Finetek, Torrance, California, USA). The immunostainings were done on a Dako Autostainer instrument (Dako, Agilent Technologies, Santa Clara, California, USA, model Link 48), and the incubation time for the primary antibodies was 20 min. CD3 was immunostained by clone SP7 (a monoclonal rabbit antibody, diluted 1:150; Thermo Scientific, Waltham, Massachusetts, USA; cat. no. RM-9107), and CD20 was immunostained by clone L26 (a mouse IgG2a antibody, diluted 1:600; Dako, cat. no. M0755). The secondary detection was performed with Dako EnVision Flex (Dako, cat. no. K8000) for 20 min, followed by diaminobenzidine (DAB) staining for 10 min. The slides were thereafter treated with CuSO4 for 5 min before counterstaining with hematoxylin. Samples were examined with a Nikon Eclipse microscope Ni-U microscope (Nikon, Tokyo, Japan) equipped with Nikon Plan-Fluor objective lenses (2×, 20×, and 40×) and images were taken with an Infinity 2 digital camera (Lumenera Corporation, Nepean, Ontario, Canada).

Results

A 62-year-old woman with seronegative rheumatoid arthritis was diagnosed in 2015 with lung adenocarcinoma, stage IIB (pT3N0Mx, TNM 7th edition). The patient, a former heavy-smoker with a smoking history of 30 pack-years, underwent right lower lobectomy. The patient had been treated with Prednisolone (usually 5 mg daily since 2005), as well as several different drugs (Methotrexate 10 mg/week for 3 weeks in 2005, Metoject 1x10 mg in 2005 and 2x10mg in 2007, Plaquenil 400 mg/day in January-February 2006, Arava 10 mg/day for 8 days in 2006, and Enbrel 50 mg/week from January 2008 to April 2009), all discontinued due to side-effects or inefficiency. Over the past six years before lung cancer diagnosis (2009–2014), the patient received seven cycles of rituximab (MabThera, 6 cycles of 2x1000mg and 1 cycle of 2x500mg) with only moderate clinical effect. Serum immunoglobulin (Ig) levels were normal before initiation of the rituximab treatment (IgG=6.1g/L; IgA=1.3g/L; IgM=2.1g/L), excluding any B-cell immunodeficiency. Serum IgA and IgM levels remained normal (IgA=20.9g/L; IgM=2.1g/L), whereas low IgG levels (4.2–5.6g/L) were observed several times over the past three years. The last rituximab cycle (2x1000mg) was given 6 months pre-operatively.

Upon informed consent, the patient was included in a research project. A pre-operative blood sample and biopsy samples from the tumor, a lung-associated lymph node, and normal lung were collected for flow cytometric analysis. For comparison, samples from a control patient with lung adenocarcinoma (not treated with rituximab) were analyzed. The control patient had CD19+ B cells in blood and tumor (Figure 1A,B). In the rituximab-treated patient, CD19+ B cells were virtually absent from the blood (Figure 1C) and strongly reduced in the tumor (0.2% of all CD45-positive
Figure 1. Flow cytometric analysis reveals the absence of tumor-infiltrating CD19+ B cells in a patient treated with rituximab. Upon chest surgery for removal of a lung tumor from a patient previously treated with rituximab, tumor biopsy and serum samples were analyzed by flow cytometry. Results from a control lung cancer patient (not treated with rituximab) are shown for comparison. Both patients were diagnosed with lung adenocarcinoma. CD45-positive leukocytes were gated and analyzed further for expression of CD19/CD3 (A–D), HLA-DR/CD14 (E–L), and CD4/CD8 (M–P). The dot plots E–H show expression of HLA-DR and CD14 by CD19-positive B cells only (red gates in A–D). Numbers in quadrants indicate the percentage of cells detected. PBMCs, peripheral blood mononuclear cells.
leukocytes, Figure 1D). The remaining CD19+ B cells in the tumor were mostly HLA-DR-negative (Figure 1H) indicating that they were plasma cells which typically lack the CD20 antigen. Rituximab did not deplete other types of immune cells, such as monocytes/macrophages, CD4+ T cells, or CD8+ T cells (Figure 1I–P). Flow cytometric analysis of a lung-associated lymph node and normal lung tissue revealed virtual absence of CD19+ B cells in the rituximab-treated patient (Figure 2).

Immunohistochemistry of formalin-fixed paraffin-embedded routine specimen was performed by staining for CD3 and CD20. In the control patient, the inflammatory infiltrate in and around the tumor contained both CD20+ B cells (Figure 3A,C) and CD3+ T cells (Figure 3E,G). In contrast, the inflammatory infiltrate in the rituximab-treated patient contained T cells (Figure 3F,H) but virtually no B cells (Figure 3B,D), in accordance with the flow cytometry data. The same pattern was observed in normal lung and in lung-associated lymph nodes. In the control patient, normal lung tissue contained peribronchial lymphoid foci with both CD20+ B cells (Figure 4A) and CD3+ T cells (Figure 4C). In contrast, the peribronchial lymphoid foci from the rituximab-treated patient contained T cells (Figure 4D) but virtually no B cells (Figure 4B). In control lung-associated lymph nodes, a normal lymphocyte distribution was observed with typical germinal centers with a high density of CD20+ B cells (Figure 5A), whereas CD3+ T cells were mostly present outside the germinal centers (Figure 5C). In sharp contrast, lung-associated lymph nodes from the rituximab-treated patient contained virtually no B cells (Figure 5B) and were homogenously and densely populated by T cells (Figure 5D). The black dots in Figure 5B represent anthracotic pigment in macrophages. Thus, rituximab therapy resulted in efficient depletion of CD20-positive B cells throughout the lungs, including in a lung tumor, in normal lung tissue, and in lung-associated lymph nodes.

**Figure 2.** Rituximab depletes B cells in lung-associated lymph node and normal lung tissue. Upon chest surgery for removal of tumor-containing lung lobe from a patient previously treated with rituximab, a lung-associated lymph node and normal lung tissue samples were analyzed by flow cytometry. Results from a control lung cancer patient (not treated with rituximab) are shown for comparison. Both patients were diagnosed with lung adenocarcinoma. Live leukocytes (CD45-positive, propidium iodide-negative) were gated and analyzed further for expression of CD19 (B cells) and CD3 (T cells). Numbers indicate the percentage of cells detected in each gate.
Figure 3. Absence of CD20+ B cells in primary lung tumor from a patient treated with rituximab. Lung tissue sections from a control patient (left) and from a rituximab-treated patient (right) were stained with anti-CD20 (A–D) or anti-CD3 (E–H) antibodies, and contrastained with hematoxylin. Both patients were diagnosed with lung adenocarcinoma. Arrowheads delineate the border of the tumor. Small boxes in A, B, E, and F indicate magnified areas in C, D, G, and H, respectively. Tu, tumor tissue. A, B, E, and F: 20× magnification; scalebar = 1 mm. C, D, G, and H: 200× magnification; scalebar = 100 μm.
Figure 4. Absence of CD20\(^+\) B cells in normal lung tissue from a patient treated with rituximab. Normal lung tissue sections from a control patient (left) and from a rituximab-treated patient (right) were stained with anti-CD20 (A,B) or anti-CD3 (C,D) antibodies, and contrastained with hematoxylin. Both patients were diagnosed with lung adenocarcinoma. Small boxes indicate areas that are magnified in the upper right inserts. LF, peribronchial lymphoid focus. Main images: 20x magnification; scalebar = 1 mm. Upper right inserts: 200x magnification.
Figure 5. Absence of CD20+ B cells in lung-associated lymph node from a patient treated with rituximab. A lung-associated lymph node from a control patient (left) and from a rituximab-treated patient (right) were stained with anti-CD20 (A–B) or anti-CD3 (C–D) antibodies, and contrastained with hematoxylin. Both patients were diagnosed with lung adenocarcinoma. The small box in B indicates the area that is magnified in the upper right insert. The black dots in B represent anthracotic pigment in macrophages. Main images: 20× magnification; scalebar = 1 mm. Upper right insert in B: 400× magnification.

Discussion
Rituximab was initially developed with the goal of eradicating B-lymphoma cells which typically reside in blood and lymphoid organs\textsuperscript{1–4}. It is now well established that rituximab efficiently eliminates normal and malignant B cells in those anatomical locations\textsuperscript{12–14}. In contrast, current knowledge on the effect of rituximab therapy in non-lymphoid tissues remains fragmentary. This is problematic because rituximab is being considered as a therapeutic option for a number of non-malignant conditions such as autoimmune diseases\textsuperscript{5–9} and myalgic encephalopathy/chronic fatigue syndrome\textsuperscript{15}. In autoimmune diseases, depletion of pathogenic B cells in inflamed tissues is likely to be required to obtain clinical benefits. In the cerebrospinal fluid of patients with multiple sclerosis, rituximab therapy was shown to result in 90–95% depletion of B cells\textsuperscript{16,17}. In the salivary glands of patients with Sjögren’s syndrome, the efficiency of rituximab remains controversial because both complete and partial depletion of B cells have been reported\textsuperscript{18,19}. Similarly, the effect of rituximab on synovial B cells is debated since various levels of depletion have been reported in patients with rheumatoid arthritis\textsuperscript{12,18,20}.

Our case report illustrates that rituximab may efficiently deplete B cells in the lungs, including lung tumor, normal lung tissue, and
lung-associated lymph nodes. This property of rituximab is of particular interest for the treatment of conditions in which pathogenic B cells reside in the lungs, such as antisyntactin syndrome, granulomatosis with polyangiitis, and scleroderma-associated interstitial lung disease. On the other hand, the strong B cell-depleting effect in the lungs may provide an explanation for the rare cases of severe non-infectious pulmonary toxicity of rituximab. Rituximab-associated lung disease is a rare but potentially fatal complication of rituximab therapy, whose pathogenic mechanism remains to be elucidated.

Rituximab therapy was associated with virtual absence of tumor-infiltrating B cells in a patient with lung adenocarcinoma. Non-small cell lung cancer (NSCLC) tumors typically contain tertiary lymphoid structures with a high frequency of CD20+ follicular B cells. Tumor-infiltrating immune cells, including B cells, may represent an ongoing protective immune response against the malignant cells. In fact, it has recently been reported that a high density of follicular B cells correlated with longer patient survival in NSCLC. Therefore, rituximab-mediated depletion of tumor-infiltrating normal B cells may potentially have a detrimental impact on the antitumor immune response, particularly in NSCLC.

**References**


**Author contributions**

HA, OTB, IØ, and AC conceived the study. AC supervised the study. JS and ÂH managed the patient. AJB, CH, BS, JS, and ÂH acquired the data. AJB, CH, BS, JS, and AC analyzed the data and prepared the figures. AC prepared the first draft of the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

**Competing interests**

The authors declare that they have no competing interests.

**Grant information**

This work was supported by grants from the Research Council of Norway, Norway Grants 2009-2014 under project contract NFI/R/2014/051 (to A. Corthay), and the Norwegian Cancer Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Acknowledgements**

We thank Ingrid Solvoll, Inger Johanne Ryan, and Kahrse Beraki for technical help.


Open Peer Review

Current Referee Status: ✔ ✔

Version 1

Referee Report 29 March 2016

doi:10.5256/f1000research.8182.r12922

Hilde Schjerven 1, Etapong Fonabei Ayongaba 1,2
1 Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, San Francisco, CA, USA
2 University of Oslo, Oslo, Norway

This well-written paper by Joly-Battaglini et al. describes a case study on the effect of Rituximab on B cells in the lung tissue and tumor microenvironment of a rheumatoid arthritis patient with lung adenocarcinoma. The authors employ the complementing techniques of flow cytometry and immunohistochemistry to show that Rituximab efficiently eliminates CD19+ B cells in the lungs and a majority of CD19+ B cells in the tumor microenvironment, without depleting other lymphoid cells which are not CD20+. Only a low percentage (0.2%) of CD19+ cells were found in the tumor, and these were suggested to be plasma cells due to lack of HLA-DR by flow cytometry.

This paper confirms the efficiency of Rituximab, and adds new knowledge on its ability to eliminate B cells in lung tissue and tumor microenvironment. The questions asked by the study were approached using appropriate methods, and the paper is clearly written.

Suggestions for minor revisions;

1. It would help the clarity of the paper if the title would indicate that it was a case study. Also, in the title, lung tumor should be corrected to singular, not plural (current title: “lung tumors”)

2. It would help the reader if the authors would comment on the life span of B cells with respect to the duration of Rituximab treatment. It would be interesting to see a discussion on whether the low percentage of presumed plasma cells observed in the tumor were from post- or pre- Rituximab treatment. Does Rituximab reach and actively deplete intra-tissue B cells, or is the depletion a result of decreased levels of circulating B cells able to infiltrate tissues, and reflects a decrease due to the life-span (or resident time) of tissue-resident B cells?

3. What could the significance of the 0.2% of plasma cells be with respect to B cell implicated diseases? This could be discussed in light of serum IgG levels and statement of the patient displaying “only moderate clinical effect”. It is interesting in regards to the discussion of use of Rituximab for treatment of B-cell mediated diseases (non-cancer) and tissue-resident B cells as opposed to circulating of lymphoid tissue B cells (see point above).
4. What is the statement “The black dots in Figure 5B represent anthracotic pigment in macrophages” based on? Although plausible, a suitable control could for instance be isotype control stain to display this as background, or CD19 (vs e.g. CD11b or similar) stain using a different secondary detection method (that would not detect anthracotic pigment). Although such added experiments might be feasible (if more material is left), it is not required, as it will not affect the main message of the paper in regards to the observed major depletion of B cells. Overall, the article is well-written, scientifically sound, and presents a case study observation that warrants indexing.

**Competing Interests:** No competing interests were disclosed.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Referee Report 03 February 2016**

doi: 10.5256/f1000research.8182.r12242

**Bertrand Huard**
Department of Oncogenesis and Biotechnology, Joseph Fourier University, Grenoble, France

Title/abstract, content, conclusions, data are all appropriate.

As a minor revision, I would ask authors to speculate on what could be the function of B cells in non infectious lung.

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Discuss this Article**

**Version 1**

Author Response 25 Feb 2016

**Alexandre Corthay**, Oslo University Hospital, Norway

Thank you very much for your comment and for making us aware of the RRID initiative which we support. RRIDs will be included in the next version of our paper.

**Competing Interests:** No competing interests were disclosed.

---

Reader Comment 23 Feb 2016
Anita Bandrowski, University of California, San Diego, USA

In testing a new tool for methods review, I detected the following research resources in your paper which did not contain the RRID (Research Resource IDentifier). As discussed in the instructions to authors, please consider adding these to the final version of your paper.

RRIDs are universal and persistent product codes and are used for antibodies, software tools and model organisms, see instructions to authors: http://f1000research.com/for-authors/article-guidelines/research-notes

Please verify the accuracy of the RRIDs below:

Needs attention, not an exact match:
Lab Vision Cat# RM-9107-R7, RRID:AB_149921
verify: scicrunch.org/resolver/RRID:AB_149921
or search: scicrunch.org/resources/Any/search?q=RM-9107

Exact match based on catalog number detected:
BioLegend Cat# 307610, RRID:AB_314688 verify: scicrunch.org/resolver/RRID:AB_314688
BioLegend Cat# 304029, RRID:AB_2174123 verify: scicrunch.org/resolver/RRID:AB_2174123
BioLegend Cat# 302227, RRID:AB_893276 verify: scicrunch.org/resolver/RRID:AB_893276
BioLegend Cat# 325617, RRID:AB_830690 verify: scicrunch.org/resolver/RRID:AB_830690
BioLegend Cat# 344713, RRID:AB_2044005 verify: scicrunch.org/resolver/RRID:AB_2044005
BioLegend Cat# 317409, RRID:AB_571954 verify: scicrunch.org/resolver/RRID:AB_571954
BioLegend Cat# 300415, RRID:AB_389310 verify: scicrunch.org/resolver/RRID:AB_389310
Dako Cat# M0755, RRID:AB_2282030 verify: scicrunch.org/resolver/RRID:AB_2282030

Please consider verifying each antibody highlighted above against the identifier and adding the syntax (vendor catalog RRID) to the final version of the paper.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com